Find generic entry opportunities
Manage your formulary budget
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Abstract:||The invention provides compositions comprising the nucleotide analog 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and an alkaline excipient with or without L-carnitine-L-tartrate. The compositions are more stable those previously described. The invention also provides methods to make the compositions and their intermediates.|
|Inventor(s):||Dahl; Terrence C. (Sunnyvale, CA), Yuan; Lung-Chi J. (Foster City, CA)|
|Assignee:||Gilead Sciences, Inc. (Foster City, CA)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Dosage form; Formulation;|
Back Citations: 8th percentile
Forward Citations: 3rd percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Taiwan||I230618||<disabled in preview>|
|Turkey||200101746||<disabled in preview>|
|New Zealand||511855||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.